STUTTGART, Germany I April 16, 2013 I La Merie Publishing is releasing its annual compilation of biologics sales since 2006. Branded products of epoetin alfa, epoetin beta and darbepoetin alfa posted 2006 sales of USD 11.94 bln. In the year 2006, erythropoietins were the best selling class of biologics ahead of any other group of biologics. Since then, sales of these branded erythropoetins (EPOs) declined with a “continuous annual decline rate” of 7.9% and achieved sales in 2012 of USD 7.2 bln (-11% vs. the previous year). This decline of EPO did not run in parallel with an increase of biosimilar EPO sales, but rather seems to be associated with a more critical use of erythropoetins and increasing price pressure from the healthcare and political systems.
Nevertheless, erythropoietins are a commercially attractive class with only a few dominating products. While biosimilar versions of EPO are widely marketed and used in non-regulated markets, the use of the very few approved biosimilar EPOs in the regulated markets is only slowly taking off. Research & development in the field of erythropoiesis stimulating agents (ESA) is going beyond erythropoietin biosimilars and variants, but is including a variety of different targets approached with antibodies, proteins, peptides, RNA and DNA.
La Merie Publishing released its Competitive Intelligence Report Erythropoiesis Stimulating Agents (ESA) as of April 2013. The report Competitor Analysis Erythropoiesis Stimulating Agents (ESA) provides information on existing first and second generation epoetin products in regulated markets, an overview on biosimilar versions of erythropoietin (EPO) in regulated markets, a compilation of novel, next generation Erythropoiesis Stimulating Agents (ESAs) separately for biologics and for oral small molecules and a summary of first generation EPO products as well as of darbepoietin biosimilar versions in less regulated markets. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date.
SOURCE: La Merie Publishing
Post Views: 131
STUTTGART, Germany I April 16, 2013 I La Merie Publishing is releasing its annual compilation of biologics sales since 2006. Branded products of epoetin alfa, epoetin beta and darbepoetin alfa posted 2006 sales of USD 11.94 bln. In the year 2006, erythropoietins were the best selling class of biologics ahead of any other group of biologics. Since then, sales of these branded erythropoetins (EPOs) declined with a “continuous annual decline rate” of 7.9% and achieved sales in 2012 of USD 7.2 bln (-11% vs. the previous year). This decline of EPO did not run in parallel with an increase of biosimilar EPO sales, but rather seems to be associated with a more critical use of erythropoetins and increasing price pressure from the healthcare and political systems.
Nevertheless, erythropoietins are a commercially attractive class with only a few dominating products. While biosimilar versions of EPO are widely marketed and used in non-regulated markets, the use of the very few approved biosimilar EPOs in the regulated markets is only slowly taking off. Research & development in the field of erythropoiesis stimulating agents (ESA) is going beyond erythropoietin biosimilars and variants, but is including a variety of different targets approached with antibodies, proteins, peptides, RNA and DNA.
La Merie Publishing released its Competitive Intelligence Report Erythropoiesis Stimulating Agents (ESA) as of April 2013. The report Competitor Analysis Erythropoiesis Stimulating Agents (ESA) provides information on existing first and second generation epoetin products in regulated markets, an overview on biosimilar versions of erythropoietin (EPO) in regulated markets, a compilation of novel, next generation Erythropoiesis Stimulating Agents (ESAs) separately for biologics and for oral small molecules and a summary of first generation EPO products as well as of darbepoietin biosimilar versions in less regulated markets. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date.
SOURCE: La Merie Publishing
Post Views: 131
